Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Pipeline

DCC-2618 KIT, PDGFRα
REBASTINIB TIE2
DCC-3014 CSF1R

Patients

Deciphera Parmaceuticals is committed to advancing improved treatments for patients with cancer.

View our current clinical trials »

Latest News

Sep
11
2017
Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress Read More »
Sep
05
2017
Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma Read More »
Aug
31
2017
Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress Read More »